COVID-19：ペプチドリーム、米メルクと共同研究：新型コロナ治療薬(動画）：
COVID-19: Research with Peptidream, Merck & Co., Inc.:new therapeutic drug for corona：
COVID-19：与肽梦公司，默克公司的合作研究：开发用于电晕的新型治疗药物
［東京 １２日 ロイター］
ペプチドリーム(4587.T)：
6月１２日、米製薬大手メルク・アンド・カンパニー(MRK.N)と共同で、新型コロナウイルス感染症治療薬の研究開発を行うと発表した。
ペプチド治療薬：
共同研究開発するペプチド治療薬は、
- 現在の新型コロナウイルスに加え、
- 将来的に発生し得る変異型コロナウイルス全般に対し
有効性が期待できる。
ペプチドリームとは：
非標準のペプチド治療薬の発見と開発を目的とした東京大学発のバイオベンチャー企業。
Article [AMP] | Reuters
https://www.google.co.jp/amp/s/jp.mobile.reuters.com/article/amp/idJPKBN23J0HR
PeptiDream Announces Collaboration with Merck & Co., Inc.,
Kenilworth, N.J., U.S.A. to Develop Candidate COVID-19 Therapies
KANAGAWA, JAPAN – June 12th, 2020 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)
today announced that it has entered into a collaboration with Merck & Co. Inc., Kenilworth NJ, USA, (“Merck”), known as MSD outside the United States and Canada, for the discovery and development of novel peptide therapeutics capable of neutralizing both the current SARS-CoV-2 virus (Coronavirus Disease “COVID19”) and potential future Coronavirus (“CoV”) outbreaks.
Under this collaboration, the companies will focus their combined efforts on developing peptide therapeutics that may be effective against multiple coronavirus strains.
The agreement builds on the original research collaboration and license agreement between both companies announced April 29, 2015.
PeptiDream will receive an undisclosed upfront payment, as well as be eligible for payments associated with the achievement of certain preclinical, clinical, as well as royalties on future sales of any products that arise from the collaboration.
“We are excited to announce this partnership focused on the discovery and development of peptide candidates targeting multiple coronaviruses. Our wide-ranging collaboration continues to make exceptional progress and I am confident that together we can make an impact in combatting this global challenge,” said Patrick C. Reid PhD, President & CEO of PeptiDream.
“Our experience has shown that good science and strong collaborations are essential to develop medicines and vaccines, and that is especially true now in a global public health emergency,” said Emma Parmee DPhil, vice president, Discovery Chemistry research,Merck & Co., Inc., Kenilworth, NJ, USA., “We look forward to working with scientists at PeptiDream to identify candidates targeting SARS CoV-2 and other coronaviruses.”
PeptiDream is pursuing a multi-pronged strategy toward identifying peptide candidates targeting different sites/regions of coronaviruses as announced previously on April 30, 2020